GB2189393A
Expired / Lapsed
GB
⏱️ 0.0 years remaining
Combination therapy using interleukin-2 and glucocorticoid
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1987-04-24
•
Granted: —
•
Expires: 2007-04-24
Abstract
Abstract Anti-tumor activity in mammals can be combatted by administering to the mammalian host a synergistically effective amount of human IL-2 and one or more glucocorticoids in combination. The composition of IL-2 and glucocorticoid(s) may be prepared in vitro or administered separately to the host. The composition is useful for treating such cancers as sarcoma. The glucocorticoid is preferably dexamethasone.
Inventors
- 👤 Edward C Bradley
- 👤 Walter J Laird
Bibliographic Details
Application Number
—
Jurisdiction
GB
Data Source
google_patents
Last Synchronized
2026-10-23 01:37
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
32 words
A composition suitable for parenteral or subcutaneous administration to mammalian hosts for the
prophylaxis ortherapeutictreatment of cancer comprising a mixture of human IL-2 and one or more
glucocorticoids in synergistically effective amounts.
Claim 2
Dependent Claim
32 words
A composition suitable for parenteral or subcutaneous administration to mammalian hosts for the
prophylaxis ortherapeutictreatment of cancer comprising a mixture of human IL-2 and one or more
glucocorticoids in synergistically effective amounts.
Claim 3
Dependent Claim
18 words
A composition according to claim 1 further comprising a pharmaceutically acceptable carrier medium for the IL-2 and steroid(s).
Claim 4
Dependent Claim
21 words
A composition according to claim 1 or 2 wherein the IL-2 is recombinant and the cancer is sarcoma or ovarian cancer.
Claim 5
Dependent Claim
14 words
A composition according to any one of claims 1-3 wherein the IL-2 is des-ala-lL2ser25.
Claim 6
Dependent Claim
14 words
A composition according to any one of claims 14 wherein the glucocorticoid is dexamethasone.
Claim 7
Dependent Claim
23 words
The use of IL-2 and one or more glucocorticoids in providing medication for the prophylaxis or therapeutic treatment of cancer in mammalian hosts.
Claim 8
Dependent Claim
23 words
The use of IL-2 and one or more glucocorticoids in providing medication for the prophylaxis or therapeutic treatment of cancer in mammalian hosts.
Claim 9
Dependent Claim
17 words
Human IL-2 and one or more glucocorticoids for use in the prophylaxis or therapeutic treatment of cancer.
Claim 10
Dependent Claim
17 words
Human IL-2 and one or more glucocorticoids for use in the prophylaxis or therapeutic treatment of cancer.
Claim 11
Dependent Claim
27 words
The use of claim 6 or IL-2 and one or more glucocorticoids according to claim 7 wherein the IL-2 and glucocorticoid(s) are administered separately to the host.
Claim 12
Dependent Claim
31 words
The use of claim 6 or IL-2 and one or more glucocorticoids according to claim 7 wherein the IL-2 and glucocorticoid(s) are mixed in vitro prior to administration to the host.
Claim 13
Dependent Claim
45 words
The use of any one of claims 6,8 or 9 or IL-2 and one or more glucocorticoids according to any one of claims 7 to 9 wherein the cancer is sarcoma or ovarian cancer, the IL-2 is a recombinant mutein, and the glucocorticoid is dexamethasone.
Claim 14
Dependent Claim
48 words
The use of any one of claims 6,8,9 or 10 or IL-2 and one or more glucocorticoids according to any one of claims 7 to 10 wherein the IL-2 and glucocorticoid(s) are in admixture with a pharmaceuticaliy acceptable carrier medium prior to administration and the host is human.
Claim 15
Independent Claim
23 words
A method of making a formulation for the prophylaxis or treatment of cancer comprising formulating together human IL-2 and one or more glucocorticoids.
Claim 16
Independent Claim
23 words
A method of making a formulation for the prophylaxis or treatment of cancer comprising formulating together human IL-2 and one or more glucocorticoids.
Claim 17
Dependent Claim
11 words
A composition according to claim 1 and substantially as hereinbefore described.
Claim 18
Dependent Claim
17 words
A composition according to claim 1 and substantially as hereinbefore described in Example 1 or
Example 2.
Claim 19
Dependent Claim
10 words
The use of claim 6 and substantially as hereinbefore described.
Claim 20
Dependent Claim
16 words
The use of claim 6 and substantially as hereinbefore described in Example 1 or Example 2.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.